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a b s t r a c t
Monkeypox virus belongs to the orthopoxvirus genus, infects rodents and monkeys in Africa, produces a
smallpox-like zoonotic disease in humans, and has the potential for global spread and exploitation for
bioterrorism. Several small animal models for studying monkeypox virus pathogenesis have been
investigated. The African dormouse is a candidate natural host but is outbred and no immunological
reagents exist. Although not a natural host, the CAST/EiJ mouse is inbred and animals and reagents are
commercially available. We compared the dissemination of monkeypox virus by bioluminescence
imaging in CAST/EiJ mice and dormice. In CAST/EiJ mice, intense replication occurred at the intranasal
site of inoculation and virus spread rapidly to lungs and abdominal organs, which had a lower virus
burden. Compared to CAST/EiJ mice, dormice exhibited a greater variation of virus spread, a slower time
course, less replication in the head and chest, and more replication in abdominal organs prior to death.
Published by Elsevier Inc.
Introduction
The orthopoxviruses comprise a genus of the chordopoxvirus
subfamily of the Poxviridae, which include members causing
disease in humans and other animals (Damon, 2007; Essbauer
et al., 2010). Variola virus, the most notorious member of this
genus, is a human-speciﬁc pathogen that caused smallpox, which
was eradicated more than three decades ago subsequent to global
vaccination with the closely related vaccinia virus (VACV) (Fenner
et al., 1988). Some orthopoxviruses, like variola virus, exhibit
pronounced host speciﬁcity. Additional examples include ectro-
melia virus, a speciﬁc mouse pathogen (Esteban and Buller, 2005)
and camelpox virus, which causes disease in camels and rarely
infects humans (Bera et al., 2011). Although the original animal
reservoir of VACV is unknown, zoonoses in Brazil and India are
caused by strains that have become prevalent in rodents, cattle
and buffalo (da Fonseca et al., 2011; Singh et al., 2012). Cowpox
virus and monkeypox virus (MPXV) primarily infect rodents but
can be transmitted to other animals as well as humans. Human
monkeypox is most prevalent in the rain forests of central Africa,
particularly the Democratic Republic of the Congo, and clinically
resembles smallpox except for lower mortality and fewer human-
to-human transmissions (McCollum and Damon, 2014; Parker
et al., 2007). A less virulent strain of MPXV is present in West
Africa and in the year 2003 was imported with infected rodents (9
African dormice, 3 rope squirrels and 2 giant pouched rats) to the
United States resulting in 47 laboratory conﬁrmed and additional
clinically diagnosed human cases (Hutson et al., 2007; Reynolds
and Damon, 2012). Sporadic human MPXV infections have also
been detected in countries neighboring the Democratic Republic of
the Congo, contributing to concerns that it may be an emerging
disease. Monkeypox virus is unlikely to be eradicated because of
its wide host range and the ready transmission from African to
North American rodents (prairie dogs) highlights the possibility
for global spread. Vaccines and therapeutics developed for control
of smallpox are also effective against MPXV and the latter is being
used as a surrogate for variola virus in non-human primate models
(Cann et al., 2013; Johnson et al., 2011; Stittelaar et al., 2006,
2005). As the most serious communicable orthopoxvirus infection
of humans, excluding variola virus, the potential exploitation of
MPXV for bioterrorism has led to the designation of Congo strains
as a Select Agent by the government of the United States of
America (http://www.selectagents.gov).
Orthopoxviruses contain a highly conserved set of genes that
are required for replication, and more variable genes that inﬂuence
host range and pathogenicity (Moss, 2007). Several small animal
models (Hutson and Damon, 2010; Parker and Buller, 2013), including
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the American black-tailed prairie dog (Guarner et al., 2004; Hutson
et al., 2009; Keckler et al., 2011; Langohr et al., 2004; Xiao et al.,
2005) and the thirteen-lined ground squirrel (Sbrana et al., 2007;
Tesh et al., 2004), have been developed for the study of MPXV
pathogenicity and to evaluate vaccines and therapeutics. Although
sensitive to infection with low doses of MPXV, these wild-caught
animals exhibit animal-to-animal variation and are difﬁcult to
breed in captivity. In addition, there is a dearth of immunological
reagents. The African dormouse, a mouse-size rodent of the family
Gliridae, was one of three MPXV-infected species in a shipment
from West Africa (Hutson et al., 2007). African dormice can be
bred in captivity, although there are no commercial sources
suitable for scientiﬁc investigations and there is also a deﬁciency
of immunological reagents (Schultz et al., 2009). Commonly used
mouse strains are highly resistant to MPXV (Hutson et al., 2010)
but a large screen identiﬁed several susceptible, wild-derived
inbred strains (Americo et al., 2010) and one of these, the CAST/
EiJ mouse, has been further studied (Earl et al., 2012). Commercial
availability of animals and reagents are advantages of this model.
However, there has been no detailed comparison of MPXV infec-
tion of CAST/EiJ mice with that of a natural host.
Bioluminescence imaging (BLI), an effective, non-invasive way
to study virus dissemination in small animal models, has been
used for VACV (Americo et al., 2014; Luker et al., 2005; Luker and
Luker, 2008; Zaitseva et al., 2009). By constructing a recombinant
virus expressing ﬁreﬂy luciferase (FL) or other luciferase enzymes,
the light emitted can be used to localize sites of infection and
quantify virus replication in a living animal. An important advan-
tage of the method is that infection can be followed over days to
weeks in the same animal. Osorio et al. (2009) investigated the
dissemination of MPXV in BALB/c and BALB/c SCID mice following
intraperitoneal inoculation. Abdominal luminescence was detected in
both the normal and immunodeﬁcient mice but systemic spread only
occurred in the latter. Recently, BLI was used to follow the dissemina-
tion of MPXV in black-tailed prairie dogs following intranasal (IN)
administration (Falendysz et al., 2014). Luminescence was detected in
superﬁcial regions but not in deep tissues such as lung, perhaps due to
the size of the animals. The purpose of the present study was to use
BLI to compareMPXV infections of the susceptible CAST/EiJ mouse, the
resistant BALB/c mouse and the African dormouse. We chose to use IN
infection as upper respiratory and mucosal routes seem likely for
human to human spread in both smallpox (Fenner et al., 1988) and
human monkeypox (Reynolds et al., 2006). However, the modes of
spread of MPXV between rodents and from rodents to humans are
uncertain.
Results
Construction and characterization of recombinant MPXV expressing
FL
Insertion of the FL open reading frame (ORF) between the F12 and
F13 ORFs of VACV strain WR has been shown to have no or minimal
effects on virus replication in cell culture or virulence in mice
(Americo et al., 2014; Luker et al., 2005). Similarly, we introduced
the FL ORF controlled by a strong synthetic VACV early/late promoter
between, and in the same orientation as, the MPXV 044 and 045 ORFs
(homologous to VACV F12 and F13). Several virus clones were isola-
ted by limiting dilution and three rounds of plaque puriﬁcation. The
Fig. 1. In vitro and in vivo characterization of MPXV-z06. (A) Growth curves. BSC-1 cells were infected with 3 PFU per cell of the parental virus (MPXV-Z79-CB2) or the
recombinant virus expressing FL (MPXV-z06). At various times after infection, cells from triplicate wells were harvested and lysed, and titers were determined by plaque
assay. (B and C) Weight loss and survival of CAST mice infected with MPXV-z06. Groups of three or four 9-week old female mice were infected IN with doses of MPXV-z06
between 2103 and 2105 PFU. Animals were monitored for weight loss (B) and death (C) for 18 days.
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recombinant clones and parental virus made plaques of similar size
and appearance and one isolate, MPXV-ZFL-06 (abbreviated MPXV-
z06), was chosen for further characterization. A one-step growth curve
was performed on BS-C-1 cells, and virus titers were determined at
successive times after infection. The kinetics of infectious virus
formation was similar for MPXV-z06 and the parental virus (Fig. 1A).
Virulence of MPXV-z06 for CAST/EiJ mice
Groups of mice were infected with 2103, 2104 or 2105
plaque forming units (PFU) of MPXV-z06 by the IN route. Mice
infected with 2105 PFU became lethargic, exhibiting hunched
posture, rufﬂed fur, and severe weight loss within a few days and
died between days 6 and 10 (Fig. 1B and C), mimicking the fate of
CAST/EiJ mice infected with the parental virus (Americo et al.,
2010). At the lower doses of 2104 and 2103 PFU, the animals
experienced less severe disease with maximum weight losses of
22% and 13%, respectively (Fig. 1B). One mouse in both the 2104
and 2103 PFU groups succumbed to the MPXV infection (Fig. 1C).
Although the MPXV-z06 was pathogenic, the lower doses pro-
duced less disease than that previously reported for the parental
virus (Americo et al., 2010). However, the data are not directly
comparable because the animals in the present study were 3 to
4 weeks older than in the previous one and resistance to MPXV
increases with age (our unpublished results).
Kinetics of MPXV-z06 spread in CAST/EiJ mice
To follow virus dissemination and replication over time, CAST/
EiJ mice were infected IN with 2104 or 2105 PFU of MPXV-z06.
Beginning on day 3 post-infection, animals were imaged every
weekday until death or clearance of virus. Pseudocolor images,
with luminescence intensity increasing from violet to red are
shown. The kinetics of virus spread in animals infected at the
lower dose is shown in Fig. 2. Due to the very high amount of
luminescence in the nasal area, animals were also imaged after
covering the head and thus lowering the threshold for visualizing
luminescence in the chest and abdomen. Accordingly, the heads
and bodies are shown separately in Fig. 2. Regions of interest (ROI)
as depicted in animal 901 RP on day 21 were drawn around the
head, chest, and abdomen and photon ﬂux was calculated. Rep-
lication in the nasal area was evident on day 3, increased daily, and
peaked between days 7 and 12. Three of the 4 animals (901 RP, 901
LP, and 901 NP) demonstrated a diminution of photon ﬂux in the
head between days 12 and 17 and subsequently cleared the virus
and recovered. In the fourth animal, luminescence reached a
maximum on day 7 but did not substantially decrease and death
occurred on day 14. The photon ﬂux in the chest and abdomen
also increased between days 3 and 7 and then gradually declined
in the three surviving animals. Although the photon ﬂux values
were similar for the chest and abdomen, MPXV replication was
Fig. 2. Bioluminescence imaging of CAST/EiJ mice infected with 2104 PFU of MPXV-z06. Four 9-week old female CAST/EiJ mice were infected IN and imaged daily on
weekdays from day 3 to day 21 post-infection. Images from representative days are shown. Exposure times were 1 s, bin¼8 for the head. Exposures of the body were 30 s at
bin¼16 with black paper covering the head. Red, blue, and purple denote intensity of luminescence from high to low. Regions of interest deﬁning the head, chest, and
abdomen (yellow boxes in animal 901 RP) were used to determine the total photon ﬂux using Living Image software.
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greater in the lung than liver and spleen due to the anatomically
related difference in attenuation of photon emission (see below
and unpublished data).
The CAST/EiJ mice infected with the higher dose of 2105 PFU
were similarly imaged (Fig. 3). Luminescence in all 3 areas of the
body was higher at this dose than in animals infected at 2104 PFU
and did not decrease with time. All animals succumbed by day 10
post-infection and the lungs, livers, and spleens were removed for
virus titration. Despite the similar photon ﬂux in the chest and
abdomen, the yields of virus from the lungs were several logs higher
than from liver or spleen. There was a good correlation (r240.95)
between photon ﬂux and virus yield in the chest.
Kinetics of MPXV-z06 spread in BALB/c mice
We also imaged MPXV spread in highly resistant BALB/c mice
for comparison. These classical inbred mice exhibit only minor
weight loss and no deaths even at a dose of 106 PFU. Nevertheless,
we previously showed that replication in the lungs of BALB/c mice
is robust, reaching levels similar to CAST/EiJ mice on days 4 to 6
post-infection (Earl et al., 2012). However, there was little spread
of MPXV to other organs in BALB/c mice and full recovery was
achieved by day 14 post-infection. Here we infected BALB/c mice
IN with 106 PFU of MPXV-z06 and imaged them from day 2 to 14.
As with CAST/EiJ mice, extensive replication was observed in the
Fig. 3. Bioluminescence imaging of CAST/EiJ mice infected with 2105 PFU of MPXV-z06. Four 9-week old female CAST/EiJ mice were infected IN and imaged daily on
weekdays from day 3 post-infection until death. Exposures of the entire body were 1 s at bin¼8. Exposures of the body with the head covered were 30 s at bin¼16. Red,
blue, and purple denote intensity of luminescence from high to low. Regions of interest deﬁning the head, chest, and abdomen (as shown in Fig. 2) were used to determine
the total photon ﬂux. On the day of death, organs were removed and virus titers determined by plaque assay.
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nasal area, so images were made without and with the heads
covered to allow better visualization of luminescence in the body
(Fig. 4). ROIs were drawn around the head, chest, and abdomen
and photon ﬂux was calculated. For the ﬁrst 5 days the photon ﬂux
in the chest and abdomen of BALB/c mice was similar to that
observed for CAST/EiJ mice; however, the photon ﬂux then rapidly
decreased.
Virulence of MPXV-z06 for African dormice
Because severe infection occurred at a lower dose of MPXV in
dormice compared to CAST/EiJ mice, dormice were infected with
only 50, 400 and 500 PFU of MPXV-z06 by the IN route. Animals
showed symptoms of lethargy, squinty eyes, rufﬂed coat, stiffness,
and lowered body temperature. At the two higher doses, all
animals succumbed between day 7 and 16 post-infection, which
was later than with CAST/EiJ mice. At the lower dose of 50 PFU
there was 60% survival (Fig. 5). We previously reported an LD50 of
12 PFU for the parental virus (Americo et al., 2010). Weight loss of
up to 25% was seen in animals that received the 400 PFU dose (not
shown).
Kinetics of MPXV-z06 spread in African dormice
We chose a dose of 400 PFU to infect dormice with MPXV-z06,
which would be comparable to the several hundred-fold higher
dose (104 and 105 PFU) used for CAST/EiJ mice with regard to
lethality. Because of constraints of our breeding colony, dormice
were older and varied more in age than the CAST/EiJ mice. Male
dormice aged 10–12 months were infected IN and imaging was
performed every 2 to 3 days. Representative luminescence images
of the infected animals are shown in Fig. 6. Luminescence was ﬁrst
detected in the head of 4 of the 6 animals (941, 942, 946, 947)
and then spread to the chest and abdomen. In 1 animal (943)
luminescence was seen ﬁrst in the abdomen and subsequently in
the head, and in one animal (944) was seen in the head only
slightly before the abdomen. The experiment in dormice was
repeated with 3 females and 1 male, aged 9 to 14 months. In
3 of those animals, luminescence was ﬁrst seen in the head while
in the fourth animal, the chest was the primary site of rep-
lication (not shown). The more variable dissemination of MPXV
in dormice contrasted with that in CAST/EiJ and BALB/c mice in
which luminescence was uniformly seen ﬁrst in the head. The
photon ﬂux increased more slowly during lethal infection of
dormice (Fig. 6) compared to CAST/EiJ mice (Fig. 4). In addition,
the photon ﬂux was similar in head, chest and abdomen of
infected dormice (Fig. 6) whereas in CAST/EiJ (Fig. 4) and BALB/c
(Fig. 5) mice the amount of luminescence in the head far exceeded
that in the body.
On the day of death, major organs from dormice infected with
400 PFU of MPXV-z06 were removed, and virus titers determined.
High titers of MPXV were found in all major organs including lung,
liver, and spleen (Figs. 6 and 7). The titers in the liver were higher
than in any other organ, in most cases by more than one log. This
contrasted with CAST/EiJ mice in which titers in the lungs were
several logs higher than in any other organ (Fig. 7).
Fig. 4. Bioluminescence imaging of BALB/c mice infected with 106 PFU of MPXV-z06. Seven 8-week old female BALB/c mice were infected IN with MPXV-z06 and imaged every
other weekday for 14 days. Exposures of whole body were 5 s at bin¼8, of the covered body were 30 s at bin¼8. Regions of interest deﬁning the head, chest, and abdomen (as
shown in Fig. 2) were used to determine the total photon ﬂux. The average total photon ﬂux for each day is shown. The experiment was performed twice with similar results.
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Discussion
BLI was useful for comparing the dissemination of MPXV in the
CAST/EiJ mouse and dormouse models as it allowed us to follow
the course of infection with both non-lethal and lethal doses and
in which there were variations between animals. However, as
previously reported (Luker et al., 2005), the ratio of photon ﬂux to
virus titer varied for different organs due in large part to the
overlying tissues. In particular, light emission from the lungs was
dramatically reduced such that similar photon ﬂuxes from the
chest and abdomen concealed nearly a three-log higher virus titer
in the lungs compared to the liver and spleen. Therefore, the
most accurate photon ﬂux comparisons are between similar
anatomic sites.
IN infection of CAST/EiJ mice resulted in initial MPXV replication in
the nasal areas followed by spread to the lungs and other internal
organs. Enhanced luminescence in the chest was detected on day 3,
peaked on day 6 and declined sharply between days 14 and 18 in
non-lethal infections. In lethal infections, there was no reduction in
luminescence and death occurred within 10 days. Similar photon
ﬂuxes were observed in the chest and abdomen but the virus titers in
the lungs were much higher than in the liver and spleen. We also
imaged MPXV spread in BALB/c mice, which are much more resistant
to MPXV than CAST/EiJ mice (Americo et al., 2010). Initially, the course
of MPXV dissemination in BALB/c mice was similar to that of CAST/EiJ,
but clearance of the infection occurred rapidly, in agreement with our
previous serial sacriﬁce studies (Earl et al., 2012). We recently found
that interferon-gamma levels in the lungs of BALB/c peaked just
before MPXV clearance whereas only low levels of this cytokine were
detected in the lungs of CAST/EiJ mice (Earl et al., 2012). It remains to
Fig. 5. Survival of African dormice infected with 50, 400, or 500 PFU of MPXV-z06.
Groups of 6–10 male and female dormice aged 4 to 14 months were infected IN
with MPXV-z06 and followed until death or for 32 days. Two mice, in the 400 PFU
group, became moribund and were euthanized.
Fig. 6. Bioluminescence imaging of African dormice infected with 400 PFU of MPXV-z06. Six male dormice from 10 to 12 months of age were infected IN with MPXV-z06.
Animals were imaged every other weekday from day 3 post-infection until death. Exposures were 5 s at bin¼8 and all were adjusted to the same color scale. Regions of
interest (yellow boxes as shown in animal D941) were drawn for quantitation of luminescence in the head, chest, and abdomen. Total photon ﬂux in each of these areas is
shown to the right of each animal. On the day of death, organs were removed and virus titers determined by plaque assay.
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be determined whether available reagents for detection of interferon-
gamma are compatible with dormice.
Spread of MPXV occurred more slowly in dormice than in CAST/EiJ
mice and the dormice exhibited greater individual variation, perhaps
reﬂecting their outbreeding. A total of 10 African dormice ranging
from 9 to 14 months were imaged, including 7 males and 3 females.
No difference in clinical disease could be attributed to either age or
gender. In most animals luminescence was detected in the abdomen
at about the same time as in the chest and was more intense there.
Furthermore, on the day of death, there were higher loads of infectious
virus in the liver than other organs, a strikingly different result than
with CAST/EiJ mice. It is relevant to compare the present BLI study
with the analysis reported by Schultz et al. (2009) in which over 100
dormice were serially sacriﬁced. In the latter study, an IN dose of
2104 PFU, which is approximately 1000 LD50 and 50X the highest
dose used in our BLI. In the majority of animals MPXV was detected in
nasal lavage on day 2 and lungs, liver and spleen on day 5. The highest
levels of MPXV were recovered from liver on day 8, the last day that
still surviving animals could be analyzed. Although the progression of
the disease was accelerated at the high dose in the previous report, the
dissemination to the various organs was similar to that of our study.
Taken together, the data suggest that MPXV dissemination in dormice
occurs through the blood or lymphatic system rather than directly
from the nasal cavity to the lungs. In contrast, MPXV dissemination
appears to occur from the nasal cavity directly to the lungs in both
BALB/c and CAST/EiJ mice. In monkeys infected either through the
aerosol, intravenous or intrabronchial route, pneumonia is prominent
andmore virus and pathological changes were found in lung than liver
or spleen (Goff et al., 2011; Johnson et al., 2011; Zaucha et al., 2001). In
humans, bronchopneumonia was diagnosed in 34 of 270 previously
unvaccinated patients and tended to occur late in disease (Jezek and
Fenner, 1988). However, the pathologies leading to death have not
been ascertained.
The use of both CAST/EiJ mice and African dormice seems
advantageous for many types of studies due to differences in the
mode of MPXV spread. Clearly, CAST/EiJ mice are superior for in depth
immunological studies because of the availability of reagents. How-




BS-C-1 cells were maintained at 37 1C and 5% CO2 in modiﬁed
Eagle minimal essential medium (EMEM; Quality Biologicals, Inc.,
Gaithersburg, MD) supplemented with 8% heat-inactivated fetal
bovine serum (FBS), 2 mM L-glutamine, 10 U of penicillin/ml, and
10 μg of streptomycin/ml.
Recombinant virus expressing FL
All procedures with MPXV were carried out in a select agent-
registered BSL-3 laboratory. The previously described clonal isolate,
MPXV-z79-CB2 (Americo et al., 2010), derived from a low passage
stock of MPXV-z79-I-005 originally obtained from I. Damon, CDC,
Atlanta, GA, was used to construct a recombinant virus expressing the
FL gene under control of an early/late synthetic promoter (Chakrabarti
et al., 1997). The FL gene was inserted between the 044 and 045 open
reading frames of MPXV-z79-CB2 as follows. DNA fragments with
approximately 600 bp of each of the insertion ﬂanks were created by
PCR. A DNA fragment containing the FL gene controlled by a synthetic
VACV early-late promoter was ampliﬁed from IHDJ-vFire (Bengali
et al., 2012). The three fragments were then fused by overlap
extension PCR. BSC-1 cells were infected with MPXV-z79-CB2 at a
multiplicity of infection of 0.05 PFU/cell and subsequently transfected
with the DNA fragment using Lipofectamine 2000 (Life Technologies,
Carlsbad, CA). After 3 days, the cells were harvested by scraping,
centrifuged, and resuspended in 0.5 ml of EMEM containing 2.5% FBS.
A limiting dilution protocol was used to isolate virus that expressed FL.
The virus was then subjected to an additional three rounds of plaque
puriﬁcation.
MPXV was puriﬁed by extraction with Genetron (1,1,2-tri-
chloro-1,2,2-triﬂuoroethane; Chemsavers, Powhatan, VA) and cen-
trifugation through a sucrose cushion as previously described
(Americo et al., 2010).
One-step growth curve
BS-C-1 cells were infected with 3 PFU per cell of MPXV in
12-well plates. One hour after infection, monolayers were washed
twice and overlaid with fresh medium. At 0, 2, 5, 8, 12, 24, 48, and
72 h after infection, cells from triplicate wells were harvested,
centrifuged, suspended in fresh medium, and stored at 80 1C.
Cells were lysed by three freeze-thaw cycles, sonicated and virus
titered in duplicate by plaque assay on BS-C-1 cells.
Animals
CAST/EiJ and BALB/c mice were obtained from Jackson Labora-
tories (Bar Harbor, ME) and Taconic Biotechnology (Germantown,
NY), respectively. African dormice (Graphiurus kelleni), originally
provided by R. Buller (St. Louis University, St. Louis, MO), were
Fig. 7. Virus yield from organs of CAST/EiJ mice and African dormice infected with a lethal dose of MPXV-z06. Ten dormice (7 male and 3 female) between 9 and 14 months
of age were infected IN with 400 PFU of MPXV-z06. Four 9-week old female CAST mice were infected IN with 2105 PFU of MPXV-z06. On the day of death, organs were
removed and virus titers were determined by plaque assay. Lung, liver, spleen, and brain are PFU/g; nasal turbinates and ovaries are total PFU.
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bred and maintained by the Comparative Medicine Branch, NIAID
as described (Kastenmayer et al., 2010). All animals were main-
tained in ventilated microisolator cages.
Inoculation of animals
MPXV-z06 was diluted in phosphate-buffered saline containing
0.05% bovine serum albumin just prior to inoculation. The virus
concentration of each dilution used for inoculation was veriﬁed by
plaque assay. Animals were anesthetized by inhalation of isoﬂurane
and IN infections were performed by instillation of 10–20 ml of virus
into one nostril. Infected CAST/EiJ mice and dormice were housed
2 to 3 per cage and one per cage, respectively. Animals were obs-
erved daily for signs of disease and weighed daily or every other day.
Most animals that succumbed to disease were found dead; none
reached the euthanasia criteria of 30% weight loss. However, two
African dormice were observed to be moribund and were euthanized
in accordance with NIAID Animal Care and Use protocols. All animal
experiments were performed in an ABSL-3 suite with approval of the
NIAID Animal Care and Use Committee and the Centers for Disease
Control.
Bioluminescence imaging
An IVIS 200 series system with a cooled charge-coupled-device
camera (Perkin Elmer, Waltham, MA) was utilized to image
animals. D-luciferin (Perkin Elmer, Waltham, MA) was injected
intraperitoneally (150 mg/g body weight) 10 min prior to imaging.
Animals were anesthetized with isoﬂurane for the duration of the
imaging procedures. Images were collected every weekday or
every other weekday from day 3 post-infection until death or
until virus was cleared. Acquisition times were from 1 s to 1 min
with varying binning factors depending on the light emission. ROI
were drawn around speciﬁc anatomic sites and light emission was
measured as photons/s/cm2/sr (photon ﬂux) using Living Image
Software. Naïve animals were similarly imaged and used for
background subtraction.
Titration of virus from organs
Lungs, livers, spleens, nasal turbinates, ovaries and brains were
removed aseptically and placed in 2–3 ml of balanced salt solution
supplemented with 0.1% bovine serum albumin and stored at
80 1C until used. Homogenization and virus plaque assays were
performed as previously described (Americo et al., 2010).
Acknowledgments
We thank Gary Luker for advice regarding BLI and the NIAID
Comparative Medicine Branch for care of animals. The research
was supported by the Division of Intramural Research, NIAID, NIH.
References
Americo, J.L., Moss, B., Earl, P.L., 2010. Identiﬁcation of wild-derived inbred mouse
strains highly susceptible to monkeypox virus infection for use as small animal
models. J. Virol. 84, 8172–8180.
Americo, J.L., Sood, C.L., Cotter, C.A., Vogel, J.L., Kristie, T.M., Moss, B., Earl, P.L., 2014.
Susceptibility of the wild-derived inbred CAST/Ei mouse to infection by
orthopoxviruses analyzed by live bioluminescence imaging. Virology 449,
120–132.
Bengali, Z., Satheshkumar, P.S., Moss, B., 2012. Orthopoxvirus species and strain
differences in cell entry. Virology 433, 506–512.
Bera, B.C., Shanmugasundaram, K., Barua, S., Venkatesan, G., Virmani, N., Riyesh, T.,
Gulati, B.R., Bhanuprakash, V., Vaid, R.K., Kakker, N.K., Malik, P., Bansal, M.,
Gadvi, S., Singh, R.V., Yadav, V., Sardarilal, Nagarajan, G., Balamurugan, V.,
Hosamani, M., Pathak, K.M.L., Singh, R.K., 2011. Zoonotic cases of camelpox
infection in India. Vet. Microbiol. 152, 29–38.
Cann, J.A., Jahrling, P.B., Hensley, L.E., Wahl-Jensen, V., 2013. Comparative pathology
of smallpox and monkeypox in man and macaques. J. Comp. Pathol 148, 6–21.
Chakrabarti, S., Sisler, J.R., Moss, B., 1997. Compact, synthetic, vaccinia virus early/
late promoter for protein expression. Biotechniques 23, 1094–1097.
da Fonseca, F.G., Kroon, E.G., Nogueira, M.L., Trindade, G.D., 2011. Zoonotic vaccinia
virus outbreaks in Brazil. Future Virol. 6, 697–707.
Damon, I., 2007. Poxviruses. In: Knipe, D.M., Howley, P.M. (Eds.), Field’s Virology,
vol. 2. Lippincott Williams & Wilkins, Philadelphia, pp. 2947–2976.
Earl, P.L., Americo, J.L., Moss, B., 2012. Lethal monkeypox virus infection of CAST/EiJ
mice is associated with a deﬁcient interferon-gamma response. J. Virol. 86,
9105–9112.
Essbauer, S., Pfeffer, M., Meyer, H., 2010. Zoonotic poxviruses. Vet. Microbiol. 140,
229–236.
Esteban, D.J., Buller, R.M.L., 2005. Ectromelia virus: the causative agent of mouse-
pox. J. Gen. Virol. 86, 2645–2659.
Falendysz, E.A., Londono-Navas, A.M., Meteyer, C.U., Pussini, N., Lopera, J.G., Osorio,
J.E., Rocke, T.E., 2014. Evaluation of monkeypox virus infection of black-tailed
prarie (Cynomys Ludovicianus) using Iin vivo bioiluminescdent imaging.
J. Wildlife Dis. 50, 524–536.
Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., Ladnyi, I.D., 1988. Smallpox and Its
Eradication, ﬁrst ed. World Health Organization, Geneva.
Goff, A.J., Chapman, J., Foster, C., Wlazlowski, C., Shamblin, J., Lin, K., Kreiselmeier,
N., Mucker, E., Paragas, J., Lawler, J., Hensley, L., 2011. A novel respiratory model
of infection with monkeypox virus in cynomolgus macaques. J. Virol. 85,
4898–4909.
Guarner, J., Johnson, B.J., Paddock, C.D., Shieh, W.J., Goldsmith, C.S., Reynolds, M.G.,
Damon, I.K., Regnery, R.L., Zaki, S.R., 2004. Monkeypox transmission and
pathogenesis in prairie dogs. Emerging Infect. Dis 10, 426–431.
Hutson, C.L., Abel, J.A., Carroll, D.S., Olson, V.A., Braden, Z.H., Hughes, C.M., Dillon, M.,
Hopkins, C., Karem, K.L., Damon, I.K., Osorio, J.E., 2010. Comparison of West African
and Congo Basin Monkeypox Viruses in BALB/c and C57BL/6 Mice. PLoS One, 5.
Hutson, C.L., Damon, I.K., 2010. Monkeypox virus infections in small animal models
for evaluation of anti-poxvirus agents. Viruses 2, 2763–2776.
Hutson, C.L., Lee, K.N., Abel, J., Carroll, D.S., Montgomery, J.M., Olson, V.A., Li, Y.,
Davidson, W., Hughes, C., Dillon, M., Spurlock, P., Kazmierczak, J.J., Austin, C.,
Miser, L., Sorhage, F.E., Howell, J., Davis, J.P., Reynolds, M.G., Braden, Z., Karem,
K.L., Damon, I.K., Regnery, R.L., 2007. Monkeypox zoonotic associations:
insights from laboratory evaluation of animals associated with the multi-state
US outbreak. Am. J. Trop. Med. Hyg. 76, 757–768.
Hutson, C.L., Olson, V.A., Carroll, D.S., Abel, J.A., Hughes, C.M., Braden, Z.H., Weiss, S.,
Self, J., Osorio, J.E., Hudson, P.N., Dillon, M., Karem, K.L., Damon, I.K.,
Regnery, R.L., 2009. A prairie dog animal model of systemic orthopoxvirus
disease using West African and Congo Basin strains of monkeypox virus. J. Gen.
Virol. 90, 323–333.
Jezek, Z., Fenner, F., 1988. Human monkeypox. Monogr. Virol 17, 1–140.
Johnson, R.F., Dyall, J., Ragland, D.R., Huzella, L., Byrum, R., Jett St, C., Claire, M.,
Smith, A.L., Paragas, J., Blaney, J.E., Jahrling, P.B., 2011. Comparative analysis of
monkeypox virus infection of cynomolgus macaques by the intravenous or
intrabronchial inoculation route. J. Virol. 85, 2112–2125.
Kastenmayer, R.J., Moak, H.B., Jeffress, E.J., Elkins, W.R., 2010. Management and care of
African Dormice (Graphiurus kelleni). J. Am. Assoc. Lab. Animal Sci 49, 173–176.
Keckler, M.S., Carroll, D.S., Gallardo-Romero, N.F., Lash, R.R., Salzer, J.S., Weiss, S.L.,
Patel, N., Clemmons, C.J., Smith, S.K., Hutson, C.L., Karem, K.L., Damon, I.K., 2011.
Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel
animal model for comparing smallpox vaccines administered preexposure in
both high- and low-dose monkeypox virus challenges. J. Virol. 85, 7683–7698.
Langohr, I.M., Stevenson, G.W., Thacker, H.L., Regnery, R.L., 2004. Extensive lesions
of Monkeypox in a prairie dog (Cynomys sp.). Vet. Pathol. 41, 702–707.
Luker, K.E., Hutchens, M., Schultz, T., Pekosz, A., Luker, G.D., 2005. Bioluminescence
imaging of vaccinia virus: Effects of interferon on viral replication and spread.
Virology 341, 284–300.
Luker, K.E., Luker, G.D., 2008. Applications of bioluminescence imaging to antiviral
research and therapy: multiple luciferase enzymes and quantitation. Antiviral
Res. 78, 179–187.
McCollum, A.M., Damon, I.K., 2014. Human monkeypox. Clin. Inf. Dis 58, 260–267.
Moss, B., 2007. Poxviridae: the viruses and their replication (Fields Virology). In: Knipe,
D.M., Howley, P.M. (Eds.), vol. 2. Lippincott Williams & Wilkins, Philadelphia,
pp. 2905–2946 (2 vols).
Osorio, J.E., Iams, K.P., Meteyer, C.U., Rocke, T.E., 2009. Comparison of monkeypox
viruses pathogenesis in mice by in vivo imaging. PLoS One 4, e6592.
Parker, S., Buller, R.M., 2013. A review of experimental and natural infections of
animals with monkeypox virus between 1958 and 2012. Future Virol. 8,
129–157.
Parker, S., Nuara, A., Buller, R.M.L., Schultz, D.A., 2007. Human monkeypox: an
emerging zoonotic disease. Future Microbiol. 2, 17–34.
Reynolds, M.G., Damon, I.K., 2012. Outbreaks of human monkeypox after cessation
of smallpox vaccination. Trends Microbiol. 20, 80–87.
Reynolds, M.G., Yorita, K.L., Kuehnert, M.J., Davidson, W.B., Huhn, G.D., Holman, R.C.,
Damon, I.K., 2006. Clinical manifestations of human monkeypox inﬂuenced by
route of infection. J. Inf. Dis 194, 773–780.
Sbrana, E., Xiao, S.Y., Newman, P.C., Tesh, R.B., 2007. Comparative pathology of
North American and central African strains of monkeypox virus in a ground
squirrel model of the disease. Am. J. Trop. Med. Hyg. 76, 155–164.
Schultz, D.A., Sagartz, J.E., Huso, D.L., Buller, R.M.L., 2009. Experimental infection of
an African dormouse (Graphiurus kelleni) with monkeypox virus. Virology 383,
86–92.
P.L. Earl et al. / Virology 475 (2015) 150–158 157
Singh, R.K., Balamurugan, V., Bhanuprakash, V., Venkatesan, G., Hosamani, M., 2012.
Emergence and reemergence of vaccinia-like viruses: global scenario and
perspectives. Indian J. Virol. 23, 1–11.
Stittelaar, K.J., Neyts, J., Naesens, L., van Amerongen, G., van Lavieren, R.F., Holy, A.,
De Clercq, E., Niesters, H.G., Fries, E., Maas, C., Mulder, P.G., van der Zeijst, B.A.,
Osterhaus, A.D., 2006. Antiviral treatment is more effective than smallpox
vaccination upon lethal monkeypox virus infection. Nature 439, 745–748.
Stittelaar, K.J., van Amerongen, G., Kondova, I., Kuiken, T., van Lavieren, R.F., Pistoor,
F.H., Niesters, H.G., van Doornum, G., van der Zeijst, B.A., Mateo, L., Chaplin, P.J.,
Osterhaus, A.D., 2005. Modiﬁed vaccinia virus Ankara protects macaques
against respiratory challenge with monkeypox virus. J. Virol. 79, 7845–7851.
Tesh, R.B., Watts, D.M., Sbrana, E., Siirin, M., Popov, V.L., Xiao, S.Y., 2004. Experi-
mental infection of ground squirrels (Spermophilius tridecemlineatus) with
Monkeypox virus. Emerging Infect. Dis 10, 1563–1567.
Xiao, S.Y., Sbrana, E., Watts, D.M., Siirin, M., da, R.A., Tesh, R.B., 2005. Experimental
infection of prairie dogs with monkeypox virus. Emerging Inf. Dis 11, 539–545.
Zaitseva, M., Kapnick, S.M., Scott, J., King, L.R., Manischewitz, J., Sirota, L., Kodihalli, S.,
Golding, H., 2009. Application of bioluminescence imaging to the prediction of
lethality in vaccinia virus-infected mice. J. Virol. 83, 10437–10447.
Zaucha, G.M., Jahrling, P.B., Geisbert, T.W., Swearengen, J.R., Hensley, L., 2001. The
pathology of experimental aerosolized monkeypox virus infection in cynomol-
gus monkeys (Macaca fascicularis). Lab. Invest. 81, 1581–1600.
P.L. Earl et al. / Virology 475 (2015) 150–158158
